Kornimate/medical-research-clean huggingface dataset:
nutritional and dietary treatment study for children/adults with autism

Conditions: Autism

Summary: 70 children and adults with autism spectrum disorders will be enrolled in a 1-year, single-blind treatment study. assessments will be conducted at the beginning and end of the study, including measurements of nutritional, metabolic, and digestive status and assessments of autism severity and overall functioning. half of the participants will be randomized into a treatment study, and half will be randomized to no changes in their current treatments. treatments will be added in a sequential manner over 12 months, including vitamin/minerals, essential fatty acids, carnitine, digestive enzymes, and healthy, gluten-free, casein-free diets. a dedicated team of nutritionists, nurses, and physicians will support and monitor the participants throughout the study. a group of 50 neurotypical children and adults, of similar age and gender, will be included for comparison.


Eligibility criteria:
inclusion criteria: inclusion criteria - autism group 1. diagnosis of autism spectrum disorder (autism, pdd-nos, or asperger's) by a psychiatrist, psychologist, or developmental pediatrician 2. verification of diagnosis by an ados evaluation (conducted by asu staff) 3. age of 2.5 years to 60 years enrollment criteria - non-autism group 1. no diagnosed mental disorders, including autism spectrum disorders, adhd, depression, anxiety, etc. 2. no first-degree relatives of individuals with autism (no siblings or parents) 3. age of 2.5 years to 60 years - exclusion criteria: exclusion criteria - autism group 1. major changes in behavioral or medical treatments in the previous two months, or intention to make such changes during the 12 months of the study. 2. usage of nutritional supplements (vitamins, minerals essential fatty acids, carnitine) or special diets in the previous two months exclusion criteria - non-autism group 1) usage of nutritional supplements (vitamins, minerals essential fatty acids, carnitine) or special diets in the previous two months -

Keywords: vitamins minerals essential fatty acids epsom salts carnitine digestive enzymes gluten-free casein-free diet
telsys - telmisartan effectiveness in isolated systolic hypertension versus systolic/diastolic hypertension patients aged 55 or older

Conditions: Hypertension

Summary: the aim of this study is to compare the effect of treatment with telmisartan on patients in whom the systolic bp is approximately 12 weeks after starting treatment under control for the first time between patients with isolated systolic hypertension (ish) at the beginning to patients with systolic/diastolic hypertension (sdh)


Eligibility criteria:
inclusion criteria: * age ≥ 55, with no upper limit * patient who has been treated and followed up for more than 12 months by the same general practitioner (gp) * hypertension measured at least once during the past 12 months and not under control at the time of inclusion in the study: * isolated systolic hypertension, namely systolic blood pressure ≥ 140 mmhg and diastolic blood pressure \< 90 mmhg or * systolic/diastolic hypertension, namely systolic blood pressure ≥ 140 mmhg and diastolic blood pressure ≥ 90 mmhg; or * systolic blood pressure ≥ 130 and diastolic blood pressure ≥ 80 mmhg, if the patient has diabetes or chronic renal insufficiency * treatment with one or more antihypertensives which remains unchanged during the month prior to collecting the data * decision by the gp to add telmisartan (either in combination with hydrochlorothiazide (hctz) or not) to the antihypertensive treatment; this decision is made by the treating doctor regardless of participation in the study. the prescription is issued in the normal way, in accordance with the conditions set down in the marketing authorisation * written informed consent of the patient to collect his/her data exclusion criteria: * the patient refuses to allow his/her data to be collected * change in the antihypertensive treatment during the month prior to collection of the data * blood pressure under control * the recommended target values corresponding to control of diastolic and systolic blood pressure are important because of the diseases associated with hypertension consequently, and in order to prevent the collection process becoming too complicated, data from patients with severe renal insufficiency or with proteinuria of ≥ 1 g/l or more are not collected in the context of this study
alcohol research consortium in hiv-intervention research arm

Conditions: HIV Positive; Alcohol Use

Summary: aim 1: examine effects of algorithm-guided alcohol treatment on alcohol consumption and alcohol use disorders (aud) symptoms. aim 2: examine effects of algorithm-guided alcohol treatment on retention in hiv care and hiv-related outcomes. aim 3: examine effects of algorithm-guided alcohol treatment on comorbid conditions

aim 1: examine effects of algorithm-guided alcohol treatment on alcohol consumption and alcohol use disorders (aud) symptoms. hypothesis 1a: patients who are treated using algorithm-guided alcohol treatment will decrease drinking quantity and or frequency compared to pre-algorithm levels. hypothesis 1b. patients who are treated using algorithm-guided treatment will decrease current aud symptoms compared to pre-algorithm symptoms levels. aim 2: examine effects of algorithm-guided alcohol treatment on retention in hiv care and hiv-related outcomes. hypothesis 2a. patients treated using algorithm-guided treatment will increase adherence to clinic visits and hiv medications compared to pre-algorithm levels. hypothesis 2b. patients who receive algorithm-guided treatment will have improved hiv biomarkers (e.g., cd4 and vl). hypothesis 3b. there will be a positive relationship between vl and alcohol consumption measured by self-report and peth level. aim 3: examine effects of algorithm-guided alcohol treatment on comorbid conditions (e.g., depression, anxiety, hcv, other drug use disorders). hypothesis 3a: persons living with hiv (plwh) with co-morbid depression and anxiety receiving algorithm-guided treatment will have better alcohol, mental health and hiv treatment outcomes compared to similar individuals in sc. hypothesis 3b: plwh with comorbid hcv receiving algorithm-guided treatment will have improved fib4 results and reduced likelihood of hcv recurrence compared to persons in sc. hypothesis 3c: other drug use will decrease among those receiving algorithm-guided treatment vs sc.

Eligibility criteria:
inclusion criteria: * at least 18 years or older; * receiving hiv care at the uab, uw or ucsd clinics and not anticipating changing clinics over the next 12 months; * audit-c score \> 3 women or \> 4 men at time of pro. exclusion criteria: * non-english speaking; * acutely suicidal, manic, acutely intoxicated, or otherwise not stable enough to provide informed consent.
early detection of children with developmental disabilities in assiut governorate

Conditions: Developmental Disability; Development Delay; Motor Delay; Down Syndrome; Autism Spectrum Disorder

Summary: the study aimed to determine the effectiveness of a designed training program for nurses toward early detection of developmental disabilities among children (0-3 years).

a group of twenty-one licensed nurses with professional experience ranging from 5 to 11 years participated in the study. the participants completed the measurements to evaluate their current knowledge, practice, and perception pre-, post-, and follow-up of the training program in relation to the early detection of disabilities.

Eligibility criteria:
inclusion criteria: * the study was conducted in selected health units in assiut, an upper egypt governorate, in selected villages: * far from the main government services, * without access to public or subsidized transportation to and from the selected villages, and * without the presence of any allied health professionals (physical therapists, occupational therapists, speech and language therapists, psychologists), who do not offer any of these medical services. the selected nurses should be * employed by the village health department in the public sector, * locals of the village where the health unit is located, * and untrained in the early identification or examination of disabled children. exclusion criteria: * other than inclusion criteria

Keywords: nurses training early detection early intervention developmental disabilities children
comparison of the effectiveness of home and hospital-based pr in candidate patients with blvr

Conditions: Emphysema; Bronchoscopic Lung Volume Reduction; Hospital-based Pulmonary Rehabilitation; Home-based Pulmonary Rehabilitation

Summary: the recent years, the use of bronchoscopic lung volume reduction in emphysema patients instead of surgical operations has become widespread. before this procedure, the implementation of pulmonary rehabilitation became a necessity. the inadequacy of the number of pulmonary rehabilitation centers in our country and in our city and the increasing number of mentioned operations have increased the need for different exercise program applications. prior to valve and coil applications in our study, changes in clinical conditions of patients will be examined if pulmonary rehabilitation is performed at home or in a hospital.

the records of emphysema patients referred to the pulmonary rehabilitation unit for prophylactic pulmonary rehabilitation prior to bronchoscopic lung volume reduction will be recorded prospectively. two parallel groups will be formed from patients with hospital-based pulmonary rehabilitation (group 1) and those with home-based pulmonary rehabilitation (group 2). the patient will receive an 8-week pulmonary rehabilitation exercise program and will be reevaluated after 8 weeks. the differences in the parameters of initial and rehabilitation end-tracing and the differences between the groups will be examined.

Eligibility criteria:
inclusion criteria: * patients with emphysema and bronchoscopic lung volume reduction procedures decided by chest physician * acceptance of participation in a 2-month pulmonary rehabilitation program. exclusion criteria: -possible orthopedic, cardiovascular or psychological disturbance that may prevent exercising.
tolerance to target doses of thiazides in actual practice: a feasibility study

Conditions: Hypertension

Summary: this is a pilot study of a method to compare common, fda-approved drugs in a clinic. instead of putting single patients into one of two drug groups, the investigators will assign the doctors who prescribe these drugs for high blood pressure into two groups. one group of doctors has agreed to prescribe mostly ("favor") one drug, chlorthalidone, if that drug would be a good choice for a patient. the other group has agreed to prescribe mostly hydrochlorothiazide. for both groups, they will try to use the doses that were shown to be protective in other trials. if the doctors mostly prescribe the drug they agreed to favor, the investigators will be able to compare outcomes, like heart attacks, in the two groups.


Eligibility criteria:
inclusion criteria: * va prescribers of thiazides for hypertension exclusion criteria: * at non-participating va sites

Keywords: prescribing patterns thiazide chlorthalidone hydrochlorothiazide target dose cluster randomized trial
pilot testing dementia-enhanced training and tool for home hospice clinicians

Conditions: Alzheimer's Disease and Related Dementias

Summary: the purpose of this study is to pilot test the feasibility, acceptability, and preliminary efficacy of a clinically useful, inclusive dementia-enhanced training and tool for use by home hospice clinicians to improve care and support for black and white patients with dementia and their family caregivers. the investigators expect family caregivers of clinicians in the intervention group will report less caregiver burden (primary outcome) than caregivers of clinicians in the control group. the investigators expect that, compared to clinicians in the control group (usual care), clinicians in the intervention group (receive the training and use the tool) will demonstrate more knowledge of dementia-related caregiving issues (secondary outcomes). in exploratory analyses, the investigators expect family caregivers will report greater self-efficacy and preparedness, and that patients of clinicians in the intervention group will experience fewer live discharges than family caregivers of patients of clinicians in the control group.

for this aim, the investigators will conduct a randomized pilot study to determine the feasibility and acceptability of implementing the training and tool in clinical practice compared to usual care with 40 clinicians (20 intervention, 20 control) and 160 black and white fcg (80 intervention, 80 control). the investigators will also determine preliminary efficacy of the training and tool. outcomes include feasibility and acceptability of the intervention, reducing fcg burden (primary outcome), improving clinician knowledge and confidence (secondary outcomes) and increasing fcg preparedness and self-efficacy.

Eligibility criteria:
inclusion criteria: * individuals are not excluded from this study based on gender. * based on proportion of hospice workforce and family caregivers that are female, we expect 70%-80% of participants will be female. * nurse, social worker, or family member who provides care to persons(s) living with dementia enrolled in home hospice care. * 19-90 years old. * can complete data collection in english. * family caregivers: identify as white or black/african american. exclusion criteria: * participant is less than 19 years old or older than 90 years old. * does not provide care to person(s) living with dementia enrolled in home hospice. * cannot complete data collection in english. * family caregiver does not identify as white or black/african american.

Keywords: dementia end of life hospice caregiver burden caregiving
an observational study of tamsulosin in patients with benign prostatic hyperplasia

Conditions: BPH; Benign Prostatic Hyperplasia

Summary: in this study, bph patients visited the institutions during the study period and the effectiveness and safety of the treatment of tamsulosin(hanmi tams® capsule) in real-practice. during the routine medical visit, according to the investigator's judgment, with diagnosis that the tamsulosin prescription is appropriate, and after deciding to start treatment, patients with bph who agreed to participate in the study were administered tamsulosin. as this study is a non-interventional observational study, all subjects received prescriptions according to the routine treatment procedure, and there were no visits or procedures required according to the observational study protocol.

this study is a multicenter, prospective, non-interventional, observational study of men administering tamsulosin(hanmi tams® capsule) to treat bph. data will be collected from patients receiving routine treatment at hospitals in south korea. each subject visit the institution according to the protocol that designed the follow-up visits for six months to examine the effectiveness and safety of tamsulosin. this study will approved by the institutions' irbs and is in compliance with clinical research ethics regulations.

Eligibility criteria:
inclusion criteria: * male was diagnosed with benign prostatic hyperplasia * those who first started taking hanmi tams® * those who voluntarily consented in writing to this study exclusion criteria: * patients for whom use of hanmi tams® is prohibited

Keywords: tamsulosin bph benign prostatic hyperplasia
haemophilus influenzae pneumonia in adults

Conditions: Haemophilus Influenzae Pneumonia

Summary: haemophilus influenzae is a gram-negative coccobacillus capable of colonizing and infecting the human respiratory tract. in the adult population, patients with an abnormality of their mucociliary epithelium and a deficiency in innate or adaptive immunity are particularly exposed. the infectious and tropical diseases department of necker-enfants malades hospital has noted a recent increase in the number of cases of respiratory infections due to h. influenzae, with a high frequency of early relapses and recurrences despite appropriate treatment. the research focuses on lower respiratory infections (pneumonia) caused by haemophilus influenzae in adults, excluding pneumonia acquired under mechanical ventilation linked to haemophilus influenzae in patients in 13 ap-hp hospitals during 12 months, from 09/01/2022 to 08/31/2023.

haemophilus influenzae is a gram-negative coccobacillus capable of colonizing and infecting the human respiratory tract. in the adult population, patients with an abnormality of their mucociliary epithelium and a deficiency in innate or adaptive immunity are particularly exposed. the infectious and tropical diseases department of necker-enfants malades hospital has noted a recent increase in the number of cases of respiratory infections due to h. influenzae, with a high frequency of early relapses and recurrences despite appropriate treatment. the research focuses on lower respiratory infections (pneumonia) caused by haemophilus influenzae in adults, excluding pneumonia acquired under mechanical ventilation linked to haemophilus influenzae in patients in 13 ap-hp hospitals during 12 months, from 09/01/2022 to 08/31/2023. the main objective of the study is to identify factors associated with relapse in hospitalized adult haemophilus influenzae pneumonia.

Eligibility criteria:
inclusion criteria: * acute respiratory symptoms: cough and/or dyspnea and/or purulent sputum or worsening of the color of the sputum for patients with chronic respiratory pathology, chest pain, desaturation defined by saturation \< 95% in ambient air * inflammatory syndrome: fever ≥ 38.5°c or crp ≥ 30 mg/l * pulmonary imaging (x-ray or ct scan) compatible with pneumonia * good quality respiratory sample (for cytobacteriological examination of sputum (cbes) : leukocytes \> 25/mm3 and cells \< 10/mm3) positive in culture for h. influenzae at a significant threshold (for cbes ≥ 107 cfu/ml, for "standard" bronchial aspirate ≥ 105 cfu/ml, for protected bronchial aspiration ≥ 103 cfu/ml, for bronchoalveolar lavage ≥ 104 cfu/ml) * respiratory antibiotic therapy started by the clinician exclusion criteria: * age \< 18 years * opposition formulated (following receipt of the study information note) * legal protection measure (impossibility of collecting non-opposition) * ventilator-associated pneumonia (vap)

Keywords: haemophilus influenzae pneumonia adult patients relapse of haemophilus influenzae pneumonia severity of haemophilus influenzae pneumonia antibiotic resistance profiles of haemophilus influenzae strains chest radiological patterns
3-year immunogenicity evaluation of quadrivalent hpv vaccine in china

Conditions: Anogenital Human Papilloma Virus Infection

Summary: the thirty-six-month immunogenicity evaluation of quadrivalent hpv (types 6, 11, 16, 18) l1 virus-like particle (vlp) vaccine in chinese female subjects aged 9 to 45 years and male subjects aged 9 to 15 years.

all eligible subjects will be enrolled for one visit. a medical history and physical examination will be conducted on all subjects. a 10 ml blood specimen will be collected. all sera should be shipped to ppd vaccines and biologics laboratory in the us. the serum specimen will be tested at ppd laboratory with competitive luminex immunoassay (clia) and multiplexed hpv immunoassay. the purpose of the quadrivalent hpv clia and multiplex is to detect neutralizing antibody and total igg to hpv virus-like particles (vlps), serotypes 6, 11, 16, 18, respectively.

Eligibility criteria:
inclusion criteria: * healthy chinese subject who participated in v501-030 in per-protocol population. * subject agrees to provide study personnel with a primary telephone number as well as an alternate telephone number for follow-up purposes. * subject is willing to give consent/assent. exclusion criteria: * subject is concurrently enrolled in clinical studies of investigational agents which may interfere with the evaluation of the study objectives. * subject has any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives * subject has a history of known prior vaccination with a hpv vaccine, either active agent or placebo after receiving the vaccination during v501-030
ate-bev early response prediction model in advanced hcc

Conditions: Hepatocellular Carcinoma; Atezolizumab-bevacizumab; Response Evaluation

Summary: the prognosis of hepatocellular carcinoma is poor compared to other carcinomas. many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. however, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. therefore, this study aimed to create a predictive model that can detect treatment response at an early stage.


Eligibility criteria:
inclusion criteria: * patients who were diagnosed with advanced hepatocellular carcinoma and who were scheduled to receive atezolizumab-bevacizumab as the first-line therapy * patients willing to participate in this study exclusion criteria: * individuals with a history of severe contrast allergy * individuals with severe comorbidities (according to the american society of clinical oncology-friends of cancer research organ dysfunction.)
reference values for body composition parameters and igf-i in the adult nordinet® international outcome study

Conditions: Growth Hormone Deficiency

Summary: the treatment of growth hormone deficiency (ghd) patients with gh, often induce fluid retention; this effect is dose dependent and temporary. the symptoms are swelling of soft tissue and joint stiffness. the objective of this study is to create bioelectric impedance/arm muscle area (bia/ama) reference data, as a measurement of hydration status, of healthy persons of both genders in the age 20-70 years.

the treatment of growth hormone deficiency (ghd) patients with gh, has since 1994 been approved in several countries. the approval is based on studies that show positive effect on body composition, physiology, lipid profile, bone density and life quality. one often observed side effect is fluid retention; this effect is dose dependent and temporary. the symptoms are swelling of soft tissue and joint stiffness. by comparing the body bioelectric impedance (bia) with an arm muscle area (ama) measurement, it is possible to determine the hydrations status of a person. this measurement is a simple and non invasive method to evaluate the gh dosages applied in the treatment of ghd persons. the objective of this study is to create bia/ama reference data of healthy persons of both genders in the age 20-70 years.

Eligibility criteria:
inclusion criteria: * healthy persons, * age 20- 70 years. exclusion criteria: * cardiac implanter (pacemaker), * heart insufficiency, chronic venuos insufficiency, * use of diuretics, desmopressin, neuroleptica, antidepressants, corticosteroids, fludrocotidon, * obesity (bmi \> 30), * knowledge of changes in electrolyte or water homeostasis.